105 related articles for article (PubMed ID: 32530468)
1. Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants.
Yu Y; Lin D; Li A; Chen Y; Ou Q; Hu H; Yao H
JAMA Netw Open; 2020 Jun; 3(6):e205837. PubMed ID: 32530468
[TBL] [Abstract][Full Text] [Related]
2. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
3. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
5. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
6. Blood-based tumour mutational burden analysis in NSCLC.
Das M
Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
[No Abstract] [Full Text] [Related]
7. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring
Wang Q; Yang Y; Yang M; Li X; Chen K
Aging (Albany NY); 2020 Jun; 12(11):10827-10843. PubMed ID: 32491995
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
9. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
10. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Katsurada M; Nagano T; Tachihara M; Kiriu T; Furukawa K; Koyama K; Otoshi T; Sekiya R; Hazama D; Tamura D; Nakata K; Katsurada N; Yamamoto M; Kobayashi K; Nishimura Y
Anticancer Res; 2019 Feb; 39(2):815-825. PubMed ID: 30711962
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
12. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
13. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
Ettinger DS; Aisner DL; Wood DE; Akerley W; Bauman J; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M; Govindan R; Gubens MA; Hennon M; Horn L; Lackner RP; Lanuti M; Leal TA; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel SP; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2018 Jul; 16(7):807-821. PubMed ID: 30006423
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
15. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
[TBL] [Abstract][Full Text] [Related]
16. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
17. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
18. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.
Gobbini E; Charles J; Toffart AC; Leccia MT; Moro-Sibilot D; Levra MG
Bull Cancer; 2020 Nov; 107(11):1098-1107. PubMed ID: 33032816
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
